- Rising numbers of surgical procedures will fuel growth.
- Wider adoption of surgical sealants and haemostat technologies.
- New emerging players in the hemostatis such as Arch Therapeutics are investment worthy for high-risk investors who are familiar with biotech start-ups.
- Arch's AC5 5 product has a competitive advantage in being superior to the existing products.
- A versatile and talented management team is vital to be successful.